COVID-19 may have distorted drug expenditures
While drug spending on employee compensation continued to decline in 2020, a report by pharmacy performance manager myMatrixx released Thursday said the workforce impact and injuries of COVID-19 could have complicated numbers.
For payers with an employee compensation program managed by myMatrixx, an Express Scripts company's prescription usage decreased 4.9% and daily costs by 2.6% in 2020. According to the report, a total of 40.7% of insurers cut drug spending this year.
However, a decrease in new entitlements for 2020 - due to widespread unemployment and the move to remote working - resulted in older entitlements “biasing” average overall drug use, resulting in a statistical increase of 12.2% at the individual injured patient level led myMatrixx referred to the "COVID distortion effect" in its report.
Meanwhile, entitlements from new workers continue to have lower drug use and lower costs, while older entitlements have higher prescription use and higher costs.
Long a downtrend, opioid spending fell 1.2% in some cases, but the rate of decline is lower than in previous years, and myMatrixx said its clinical team "is investigating possible causes for this trend, particularly in terms of the COVID bias effect ".
The report also found that compensable treatment for COVID-19 symptoms had "minimal impact" on retail prescription spending, accounting for less than 0.25% of total spending.
Further news on insurance and employee compensation for the coronavirus crisis can be found here.
read more
https://businessservicesnews.ca/covid-19-may-have-distorted-drug-expenditures/
Comments
Post a Comment